Improved antiviral activity of the aryloxymethoxyalaninyl phosphoramidate (APA) prodrug of abacavir (ABC) is due to the formation of markedly increased carbovir 5′‐triphosphate metabolite levels

FEBS Letters - Tập 573 - Trang 38-44 - 2004
Jan Balzarini1, Stefano Aquaro2, Alshaimaa Hassan-Abdallah3, Susan M. Daluge4, Carlo-Federico Perno2, Chris McGuigan3
1Rega Institute for Medical Research, K. U. Leuven, B-3000 Leuven, Belgium
2Department of Experimental Medicine, University of Rome “Tor Vergata”, I-00135 Rome, Italy
3Welsh School of Pharmacy, University of Wales Cardiff, Cardiff, Wales CF10 2XF, UK
4GlaxoSmithKline, Research Triangle Park, NC 27709, USA

Tóm tắt

The anti‐human immunodeficiency virus (HIV) activity of abacavir (ABC; 1‐(1S,4R)‐4‐[2‐amino‐6‐(cyclopropylamino)‐9H‐purin‐9‐yl]‐2‐cyclopentene‐1‐methanol) could be markedly enhanced by administering the aryloxymethoxyalaninyl phosphoramidate prodrug derivative of ABC (pro‐ABC‐MP) to virus‐infected cell cultures. Metabolic studies with radiolabeled ABC and pro‐ABC‐MP in human T‐lymphocyte and primary macrophage cell cultures revealed a significantly increased delivery of the activated (phosphorylated) metabolite of ABC (ABC‐MP) by pro‐ABC‐MP, and the concomittant appearance of markedly higher intracellular levels of carbovir 5′‐triphosphate (CBV‐TP), which represents the eventual antivirally active metabolite of ABC. The intracellular amounts of ABC‐MP and appearance of CBV‐TP closely correlated with the extracellular pro‐ABC‐MP concentrations that were administered to the cell cultures within a concentration range between 0.5 and 100 μM. The highest amounts of CBV‐TP were observed within 6–24 h after drug administration. The improved delivery of ABC‐MP and metabolic conversion to CBV‐TP explain the markedly enhanced antiviral activity of the prodrug of ABC, and warrant further exploration of this prodrug technology on ABC and related compounds to further enhance and optimize their antiviral efficacy.

Tài liệu tham khảo

10.1128/AAC.41.5.1082 10.1128/AAC.41.5.1099 10.1016/0166-3542(95)94766-U Johnson M.A., 1989, Mol. Pharmacol., 36, 291 10.1016/S0021-9258(19)36820-6 1999 Williams &#x0026; Wilkins Baltimore J. Balzarini E. De Clercq T.C. Merigan J.G. Bartlett D. Bolognesi Textbook of AIDS Medicine 815 847 10.1016/S0021-9258(18)83322-1 Balzarini J., 1987, Mol. Pharmacol., 32, 162 Balzarini J., 1987, Mol. Pharmacol., 32, 798 10.1016/S0021-9258(19)75738-X 10.1073/pnas.93.14.7295 10.1021/jm950605j 10.1016/0960-894X(96)00433-7 10.1006/bbrc.1996.1181 10.1021/jm970664s 10.1021/jm981096z 10.1124/mol.58.5.928 10.1124/mol.56.6.1354 10.1002/1098-1128(200011)20:6<417::AID-MED1>3.0.CO;2-Z 10.1016/0166-3542(91)90274-U 10.1055/s-1998-1637 Sastry J.K., 1992, Mol. Pharmacol., 41, 441 10.1177/095632029400500205 10.1016/S0960-894X(01)80709-5 10.1128/AAC.44.1.173-177.2000 10.1016/S0006-291X(88)80950-1 Trennery P. Personal communication Ching S.V. Ayers K.M. Dornsife R.E. Grebe G.L. and Howard J.L. (1994) Abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology Washington DC I88 p. 92 10.1002/jlb.62.1.138
Thông tin
Thông tin xuất bản

FEBS Letters

Tập 573

38-44

Thông tin tác giả